Maraviroc (A8311): Selective CCR5 Antagonist for HIV-1 Entry and Neuroinflammation Research

Executive Summary: Maraviroc (UK-427857, Selzentry) is a potent, selective small-molecule antagonist of the chemokine receptor CCR5, used in advanced HIV-1 and neuroinflammation research. It blocks the gp120-CCR5 interaction, inhibiting R5-tropic HIV-1 entry into host cells with an IC₅₀ of ~2.0 nM in cellular assays (APExBIO). Maraviroc also inhibits the binding of chemokines MIP-1α, MIP-1β, and RANTES at nanomolar concentrations. Solubility is ≥25.7 mg/mL in DMSO and ≥48 mg/mL in ethanol, but it is insoluble in water. The compound is a key tool for dissecting CCR5-mediated signaling in HIV tropism, neuroinflammatory diseases, and ischemic stroke models (Xiao et al., 2025).

Biological Rationale

CCR5 is a G protein-coupled receptor (GPCR) expressed on T cells, macrophages, and dendritic cells, serving as a principal coreceptor for R5-tropic HIV-1 strains. The HIV-1 envelope glycoprotein gp120 utilizes CCR5, in concert with CD4, for viral entry into host immune cells (APExBIO). Besides its role in viral entry, CCR5 signaling mediates chemotaxis, immune cell trafficking, and neuroinflammatory responses. In the context of ischemic stroke, CCR5 activity is implicated in the recruitment of leukocytes and exacerbation of blood-brain barrier (BBB) disruption, contributing to secondary brain injury (Xiao et al., 2025).

Mechanism of Action of Maraviroc

Maraviroc functions as a non-competitive allosteric antagonist of CCR5. By binding to a transmembrane pocket of CCR5, it induces a conformational change that prevents gp120 from interacting with the receptor (APExBIO). This action effectively blocks HIV-1 fusion and entry into susceptible cells. Maraviroc also inhibits the binding of endogenous chemokines MIP-1α (IC₅₀ ≈ 3.3 nM), MIP-1β (IC₅₀ ≈ 7.2 nM), and RANTES (IC₅₀ ≈ 5.2 nM) to CCR5. In neuroinflammation and stroke models, Maraviroc modulates CCR5/ERK/CREB and MAPK/NF-κB signaling pathways, reducing leukocyte infiltration and cytokine release (Xiao et al., 2025).

Evidence & Benchmarks

• Maraviroc inhibits HIV-1 Ba-L infection in human PBMCs with an IC₅₀ of ~2.0 nM (APExBIO).
• Blocks MIP-1α, MIP-1β, and RANTES binding to CCR5 at IC₅₀ values of 3.3 nM, 7.2 nM, and 5.2 nM, respectively (APExBIO).
• Maraviroc reduces leukocyte infiltration and neuroinflammatory cytokine release in ischemic stroke models (Xiao et al., 2025).
• Maintains 100% solubility at ≥25.7 mg/mL in DMSO and ≥48 mg/mL in ethanol (25°C) (APExBIO).
• Recommended storage is desiccated at -20°C; aqueous solutions are not stable for long-term storage (APExBIO).

Compared to broader reviews such as this APExBIO-linked guide which focuses on troubleshooting and workflows, this article provides quantitative benchmarks and clarifies Maraviroc's verified limits in HIV and neuroinflammation models.

The Selzentry-focused article highlights workflow strategies, while this review extends those by integrating recent peer-reviewed evidence for ischemic stroke applications.

For advanced mechanistic perspectives, see this mechanistic analysis; in contrast, the current article details storage, solubility, and concentration benchmarks for experimental reproducibility.

Applications, Limits & Misconceptions

Maraviroc is widely used in:

• HIV-1 entry inhibition assays and viral tropism studies.
• Delineating CCR5-dependent signaling in immune cells.
• Modeling neuroinflammatory mechanisms in ischemic stroke and related CNS disorders (Xiao et al., 2025).
• Evaluating chemokine binding dynamics and downstream pathway activation (MAPK/NF-κB, ERK/CREB).

Maraviroc is not intended for clinical or diagnostic use in its research formulation. Efficacy is limited to R5-tropic HIV-1 strains; it does not block entry of X4-tropic or dual-tropic viruses. It is insoluble in water, making DMSO or ethanol the preferred solvents. Maraviroc's effects on CCR5-negative cells or non-CCR5 pathways are negligible.

Common Pitfalls or Misconceptions

• Maraviroc does not inhibit X4-tropic HIV-1 strains or viruses that use CXCR4 as a coreceptor.
• It is ineffective in models lacking CCR5 expression.
• Water-based solutions are unstable and not recommended for storage or dosing.
• Maraviroc is not a pan-chemokine receptor blocker; selectivity is for CCR5 only.
• Research use only: not for therapeutic, human, or veterinary application.

Workflow Integration & Parameters

Maraviroc is supplied by APExBIO as a 10 mM solution in DMSO (SKU: A8311) or as a powder (product page). For cell-based assays, recommended working concentrations range from 0.5 nM to 1 μM, depending on viral or chemokine sensitivity. Stock solutions should be prepared in DMSO or ethanol; avoid aqueous dilution beyond experimental timeframes. Store powder desiccated at -20°C and avoid repeated freeze-thaw cycles. For stability, use freshly prepared solutions and minimize exposure to moisture. Maraviroc is compatible with standard virology, immunology, and neuroscience assay protocols, including flow cytometry, ELISA, western blot, and live-cell imaging. For detailed troubleshooting and workflow tips, consult linked articles such as this comparative insights guide.

Conclusion & Outlook

Maraviroc (A8311) is a gold-standard, selective CCR5 antagonist for dissecting HIV-1 entry and neuroinflammatory signaling. Quantitative benchmarks and robust solubility enable precise experimental design. Its role in modulating neuroinflammation and ischemic injury highlights translational potential (Xiao et al., 2025). APExBIO's Maraviroc is a reference compound for advanced research in virology and neuroimmunology.